Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$21.69
-0.9%
$21.18
$17.24
$28.56
$14.04B0.941.25 million shs635,193 shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$214.50
-0.9%
$209.58
$170.00
$292.80
$14.30B0.9122 shs1 shs
Moderna, Inc. stock logo
MRNA
Moderna
$30.97
-0.9%
$28.02
$23.15
$125.68
$12.09B1.848.95 million shs5.76 million shs
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$55.82
+0.1%
$62.58
$54.95
$141.74
$3.96B0.68335 shs201 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
-0.87%+1.07%+2.50%+7.01%-21.84%
Genmab A/S stock logo
GNMSF
Genmab A/S
-0.88%-0.21%+1.61%+8.28%-21.15%
Moderna, Inc. stock logo
MRNA
Moderna
-0.93%-5.78%+19.58%+20.32%-74.43%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.00%-3.02%-5.63%-7.26%-55.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
4.1221 of 5 stars
3.35.00.00.03.80.03.1
Genmab A/S stock logo
GNMSF
Genmab A/S
0.3682 of 5 stars
0.01.00.00.02.20.01.3
Moderna, Inc. stock logo
MRNA
Moderna
4.235 of 5 stars
4.01.00.04.61.82.50.6
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.64
Moderate Buy$37.8074.27% Upside
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6150.50% Upside
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
3.80
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ZLDPF, GNMSF, GMAB, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Hold
7/8/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
7/7/2025
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/1/2025
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.12B4.46$1.50 per share14.43$8.04 per share2.70
Genmab A/S stock logo
GNMSF
Genmab A/S
$3.12B4.54$15.05 per share14.25$80.53 per share2.66
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.70N/AN/A$28.33 per share1.09
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$9.09M436.12N/AN/A$17.59 per share3.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.7612.3212.196.6535.11%18.08%14.52%8/14/2025 (Estimated)
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.14B$17.6312.17N/A35.11%19.23%15.44%8/7/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%8/1/2025 (Estimated)
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
-$156.43M-$2.49N/AN/AN/A-2,127.09%-13.40%-12.28%8/13/2025 (Estimated)

Latest ZLDPF, GNMSF, GMAB, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.39N/AN/AN/AN/AN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.97N/AN/AN/A$116.26 millionN/A
5/8/2025Q1 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
5/8/2025Q1 2025
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.88$3.05+$1.17$3.05$761.09 million$765.14 million
5/8/2025Q1 2025
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
-$0.77-$0.67+$0.10-$0.67$248.61 million$1.14 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
5.34
5.32
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
5.34
5.32
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.03
25.10
25.07

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A

Insider Ownership

CompanyInsider Ownership
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Genmab A/S stock logo
GNMSF
Genmab A/S
1.54%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.54 million631.66 millionOptionable
Genmab A/S stock logo
GNMSF
Genmab A/S
2,68266.07 million65.06 millionNot Optionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
34071.02 millionN/ANot Optionable

Recent News About These Companies

Zealand Pharma appoints Utpal Singh as CSO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$21.69 -0.19 (-0.87%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$21.73 +0.04 (+0.20%)
As of 07/21/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S stock logo

Genmab A/S OTCMKTS:GNMSF

$214.50 -1.90 (-0.88%)
As of 07/21/2025 09:30 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Moderna stock logo

Moderna NASDAQ:MRNA

$30.97 -0.29 (-0.93%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$31.08 +0.11 (+0.36%)
As of 07/21/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Zealand Pharma A/S stock logo

Zealand Pharma A/S OTCMKTS:ZLDPF

$55.82 +0.06 (+0.10%)
As of 07/18/2025 01:25 PM Eastern

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.